Trial Profile

Phase II Study of Pazopanib in Patients With Progressive Recurrent or Metastatic Salivary Gland Carcinoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 31 Oct 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pazopanib (Primary)
Indications Carcinoma; Salivary gland cancer
Focus Therapeutic Use
Acronyms PACSA; PACSA-ORL02
Sponsors UNICANCER

Most Recent Events

25 Oct 2019 Status changed from active, no longer recruiting to completed.
06 Feb 2019 Planned End Date changed from 1 Aug 2018 to 1 Sep 2019.
11 Oct 2016 Results assessing efficacy of pazopanib including tumor growth rates analysis presented at the 41st European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com